Firm says platform adds enhanced capacity to manufacture proteins.



Phyton Biotech acquired Dow Chemical’s technology and intellectual property platform for the engineering of glycosylation in pharmaceutical protein products.


This transaction will be enhanced through a research collaboration with the Dutch research institute Plant Research International, part of Wageningen University & Research Centre and one of the innovators of the technology platform, according to Phyton.


The Dow agreement coincides with the installation of a second 75,000-liter bioreactor at Phyton’s German cell fermentation facility.